Aakash Desai/LinkedIn
Dec 19, 2024, 11:58
Aakash Desai: Exciting news for extensive-stage small-cell lung cancer
Aakash Desai, Assistant Professor at UAB O’Neal Comprehensive Cancer Center, posted on LinkedIn:
“Exciting news for extensive-stage small-cell lung cancer (ES-SCLC)!
The FDA has granted breakthrough therapy designation (BTD) to sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients whose disease has progressed after platinum-based chemotherapy.
Key findings from the phase II TROPiCS-03 trial:
- Overall Response Rate (ORR): 41.9%.
- Disease Control Rate: 83.7%.
- Clinical Benefit Rate: 48.8%.
- Median Duration of Response: 4.7 months.
The favorable safety and efficacy data are paving the way for phase III trials. Hopefully, this BTD marks a step forward in improving outcomes for ES-SCLC patients.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 19, 2024, 11:58
Dec 19, 2024, 11:54
Dec 19, 2024, 11:53
Dec 19, 2024, 11:23
Dec 19, 2024, 08:27
Dec 19, 2024, 08:12
Dec 19, 2024, 08:08
Dec 19, 2024, 07:51
Dec 19, 2024, 07:45